Pediatrics · Medical Literature
Efficacy and safety of short- versus standard-course ceftriaxone therapy in children with pneumonia: A randomized trial.
Abstract
Pediatric bacterial pneumonia (30-40% of cases) is commonly treated with ceftriaxone sodium, but optimal duration (traditional 7-14 days vs. short 5-7 days) remains controversial. To compare therapeutic efficacy, inflammatory marker dynamics and safety of short- vs. standard-course ceftriaxone sodium in pediatric pneumonia. This prospective, single-center, single-blind, phase randomized controlled trial randomized 200 children (1-14 years) 1:1 to short-course (5-7 days) or standard-course (7-14 days) ceftriaxone sodium. The primary outcome was overall response rate; secondary outcomes included symptom relief time, hospital stay, recurrence, adverse events, and changes in lung function and inflammatory markers. Symptom relief time and overall efficacy were comparable between groups (P>0.05). Short-course ceftriaxone sodium reduced hospital stay and adverse events (P<0.05), while standard-course lowered recurrence rate and achieved superior inflammatory marker normalization by day 5 (P<0.05). Short- and standard-course ceftriaxone sodium have similar overall efficacy. A short-course is suitable for mild cases with a prompt inflammatory response, while a standard-course is preferred for severe cases or delayed inflammation to prevent relapse.
Clinical relevance
In children aged 1–14 years with bacterial pneumonia, does short-course ceftriaxone (5–7 days) achieve comparable overall therapeutic efficacy to standard-course ceftriaxone (7–14 days) while offering a superior safety profile? __SNAPSHOT__ {"studyDesign":"Prospective, single-center, single-blind, randomized controlled trial","setting":"Single center; country not explicitly stated in abstract (publication in Pakistan Journal of Pharmaceutical Sciences; institutional setting not further described)","sampleSize":"n=200 (short-course: n=100, standard-course: n=100; 1:1 allocation)","population":"Children aged 1–14 years with bacterial pneumonia (estimated 30–40% of all pediatric pneumonia cases per abstract background)","intervention":"Short-course intravenous ceftriaxone sodium: 5–7 days","comparator":"Standard-course intravenous ceftriaxone sodium: 7–14 days","primaryOutcome":"Overall response rate (overall efficacy)","followUp":"Not reported beyond the treatment and acute assessment period; duration of post-discharge follow-up for recurrence assessment not specified","fundingSource":"Not reported"}
Key findings
The primary outcome — overall response rate — was comparable between the short-course (5–7 days) and standard-course (7–14 days) ceftriaxone groups (P>0.05); exact response rates, absolute risk difference, relative risk, confidence intervals, and NNT are not reported in the available abstract. Symptom relief time was similarly not statistically different between groups (P>0.05). Short-course therapy was associated with shorter hospital stay and fewer adverse events (both P<0.05), though the absolute magnitude of these differences, specific adverse event types, and incidence rates are not reported. Standard-course therapy was associated with a lower recurrence rate and superior normalization of inflammatory markers by day 5 (both P<0.05); again, absolute rates, confidence intervals, and specific inflammatory markers (though high-sensitivity CRP [hs-CRP] is listed as a keyword) are not provided in the abstract. No NNT or NNH can be calculated from the available data. No serious or fatal adverse events are specifically described.
Practice implications
This trial provides directional evidence that short-course ceftriaxone (5–7 days) is non-inferior in overall efficacy to standard-course therapy (7–14 days) for pediatric bacterial pneumonia, while reducing hospital length of stay and adverse event burden — findings consistent with the broader short-course antibiotic literature in pediatric CAP. The authors suggest that short-course therapy is appropriate for mild disease with prompt inflammatory response, while standard-course therapy is preferred for more severe or complicated cases; however, the criteria used to define 'mild' versus 'severe' cases, or what constitutes a 'prompt inflammatory response,' are not operationally defined in the abstract. Critically, this summary is based on the abstract only — the full study methods, randomization procedures, blinding details, statistical analysis plan, and complete results tables are unavailable for review. The single-blind design (rather than double-blind) introduces risk of performance and detection bias, particularly for subjective outcomes such as symptom relief time. The single-center design and unspecified geographic setting limit generalizability. The finding of lower recurrence with standard-course therapy deserves attention, as it may have clinical significance for children at higher risk of treatment failure or complicated pneumonia. The absolute recurrence difference is unknown from the abstract, preventing meaningful clinical risk-benefit analysis. This study does not establish definitive non-inferiority (no non-inferiority margin is described), and results should be interpreted as hypothesis-supporting rather than practice-changing. __LIMITATIONS__ Abstract-only availability: key methodological and statistical details (randomization concealment, blinding procedures, ITT vs. per-protocol analysis, power calculations, attrition) are not assessable.,Single-blind design: lack of double-blinding introduces performance bias (clinician decisions) and detection bias (subjective outcome assessment), particularly for symptom relief time and adverse event reporting.,Single-center study: limits generalizability across healthcare systems, pathogen epidemiology, and antibiotic resistance patterns.,Sample size of 200 is modest; no information on power calculation or whether the trial was adequately powered to detect non-inferiority or meaningful differences in recurrence or adverse events.,No non-inferiority margin pre-specified (not reported): it is unclear whether the primary outcome was tested for non-inferiority or equivalence versus superiority, limiting interpretation of the P>0.05 findings.,Heterogeneous treatment windows in both arms (5–7 days vs. 7–14 days) create within-group variation that could obscure true dose-response relationships and complicate interpretation.,Follow-up duration for recurrence is not specified, making the recurrence outcome difficult to interpret clinically.,Specific adverse events, their severity, and their incidence rates are not reported, limiting safety assessment.,Funding source not reported; potential conflicts of interest cannot be evaluated.,Disease severity stratification and inclusion/exclusion criteria are insufficiently described in the abstract to determine which patient populations the results apply to.,No information on microbiologic confirmation of bacterial pneumonia, pathogen type, or antibiotic susceptibility, which may affect the generalizability of ceftriaxone-specific findings. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ Short-course ceftriaxone (5–7 days) demonstrated comparable overall efficacy to standard-course therapy (7–14 days) in hospitalized children with bacterial pneumonia, with fewer adverse events and shorter hospital stay, but standard-course therapy was associated with lower recurrence and superior inflammatory marker normalization. These results are directionally consistent with the broader evidence base supporting antibiotic de-escalation in mild pediatric pneumonia, but the single-blind, single-center design and abstract-only availability preclude definitive practice change. Clinicians should continue to individualize antibiotic duration based on disease severity, clinical trajectory, and local guidelines, pending confirmation from adequately powered, double-blind trials.